OpportunityTitle: In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required
AdditionalInformationOnEligibility: Eligible OrganizationsHigher Education InstitutionsPublic/State Controlled Institutions of Higher EducationPrivate Institutions of Higher EducationThe following types of Higher Education Institutions are always encouraged to apply for FDA support as Public or Private Institutions of Higher Education:Hispanic-serving InstitutionsHistorically Black Colleges and Universities (HBCUs)Tribally Controlled Colleges and Universities (TCCUs)Alaska Native and Native Hawaiian Serving InstitutionsAsian American Native American Pacific Islander Serving Institutions (AANAPISIs)Nonprofits Other Than Institutions of Higher EducationNonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)For-Profit OrganizationsSmall BusinessesFor-Profit Organizations (Other than Small Businesses)GovernmentsState GovernmentsCounty GovernmentsCity or Township GovernmentsSpecial District GovernmentsIndian/Native American Tribal Governments (Federally Recognized)Indian/Native American Tribal Governments (Other than Federally Recognized)U.S. Territory or PossessionOtherIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions)
Description: Locally-acting orally inhaled drug products (OIDPs) treat various pulmonary diseases by targeting relevant lung tissue via aerosolized medicine. Regional deposition models are useful for understanding the in vivo performance of OIDPs but require comparator data to support their use for product development purposes. In vivo imaging studies of regional deposition, using techniques such as gamma scintigraphy or single photon emission computed tomography (SPECT) /computed tomography (CT) can provide comparator data for regional deposition models, but the data collected may not be ideally suited to comparison with model predictions. For example, gamma scintigraphy studies produce two-dimensional region specific data while model predictions produce three-dimensional lung generation-level information. The purpose of this funding opportunity announcement is to support the conduct of an in vivo imaging study that uses gamma scintigraphy or SPECT/CT techniques to measure regional lung deposition in human subjects following administration of at least one OIDP with data analysis procedures that are optimized to facilitate a direct comparison with model predictions of branch-level deposition, thereby supporting model validation.
GrantorContactEmailDescription: shashi.malhotra@fda.hhs.gov
GrantorContactText: Shashi Malhotra &lt;br/&gt;Grants Management Specialist &lt;br/&gt;Phone 2404027592